Promoted Oral Alzheimer's Disease Phase 3 Clinical Trial

A few days ago, Alzheon announced the completion of a $50 million Series D financing, which will be used to accelerate the Phase 3 clinical trial APOLLOE4 of its oral investigational therapy ALZ-801 (valiltramiprosate) for the treatment of early Alzheimer's disease, and potential Regulatory applications

ALZ-801 is an oral drug in Phase 3 clinical development that blocks the formation of soluble amyloid oligomers associated with cognitive decline in Alzheimer's disease process potential

In February, the company announced positive biomarker results from a Phase 2 clinical trial of ALZ-801

The results of the phase 2 clinical trial including 80 patients showed that the plasma p-tau181 level in the ALZ-801 group was significantly reduced by 29% (p=0.

In addition to biomarker results, the Phase 2 clinical study also included the Rey Auditory Verbal Learning Test (RAVLT) as a secondary endpoint

Martin Tolar, founder, president and CEO of Alzheon, said: "Alzheon develops differentiated solutions for the treatment and prevention of Alzheimer's disease

References:

[1] Alzheon Announces Closing of Oversubscribed $50 Million Series D Financing Round to Accelerate Completion of APOLLOE4 Phase 3 Trial and Expansion of Product Portfolio.